Akero Therapeutics Statistics
Share Statistics
Akero Therapeutics has 79.68M
shares outstanding. The number of shares has increased by 15.14%
in one year.
| Shares Outstanding | 79.68M |
| Shares Change (YoY) | 15.14% |
| Shares Change (QoQ) | 14.07% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 963 |
| FTD / Avg. Volume | 0.08% |
Short Selling Information
The latest short interest is 6.78M, so 8.51% of the outstanding
shares have been sold short.
| Short Interest | 6.78M |
| Short % of Shares Out | 8.51% |
| Short % of Float | 8.76% |
| Short Ratio (days to cover) | 6.14 |
Valuation Ratios
The PE ratio is -7.41 and the forward
PE ratio is -8.61.
Akero Therapeutics's PEG ratio is
-0.25.
| PE Ratio | -7.41 |
| Forward PE | -8.61 |
| PS Ratio | 0 |
| Forward PS | 9.4 |
| PB Ratio | 2.49 |
| P/FCF Ratio | -8.12 |
| PEG Ratio | -0.25 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Akero Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 19.38,
with a Debt / Equity ratio of 0.05.
| Current Ratio | 19.38 |
| Quick Ratio | 19.38 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | -0.13 |
| Debt / FCF | -0.16 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-4,000,952.38 |
| Employee Count | 63 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 102.95% in the
last 52 weeks. The beta is -0.13, so Akero Therapeutics's
price volatility has been lower than the market average.
| Beta | -0.13 |
| 52-Week Price Change | 102.95% |
| 50-Day Moving Average | 41.81 |
| 200-Day Moving Average | 34.33 |
| Relative Strength Index (RSI) | 44.56 |
| Average Volume (20 Days) | 1,214,475 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -285.42M |
| Net Income | -252.06M |
| EBITDA | -285.42M |
| EBIT | -256.73M |
| Earnings Per Share (EPS) | -3.75 |
Full Income StatementBalance Sheet
The company has 340.24M in cash and 36.46M in
debt, giving a net cash position of 303.78M.
| Cash & Cash Equivalents | 340.24M |
| Total Debt | 36.46M |
| Net Cash | 303.78M |
| Retained Earnings | -826.16M |
| Total Assets | 825.89M |
| Working Capital | 730.63M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -230.11M
and capital expenditures 0, giving a free cash flow of -230.11M.
| Operating Cash Flow | -230.11M |
| Capital Expenditures | n/a |
| Free Cash Flow | -230.11M |
| FCF Per Share | -3.43 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
